Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: A retrospective observational analysis

Transfusion

Volumn 49, Issue 3, 2009, Pages 570-577

  Berkhof, Farida F ^a   Eikenboom, Jeroen C J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ALLOPATHY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG INDICATION; ERYTHROCYTE TRANSFUSION; FEMALE; HOSPITAL DISCHARGE; HUMAN; INFORMATION PROCESSING; LABORATORY TEST; MALE; MEDICAL INFORMATION; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD CELL COUNT; BLOOD TRANSFUSION; FACTOR VIIA; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 60349126876     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.02001.x     Document Type: Article

References (26)

1. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002 42 : 114 24.
2. Kogler VM, Slobodnjak Z, Samarzija M, Macan FS, Karadza V, Fakopovic M. Successful use of activated recombinant factor VII in life-threatening bleeding after thoracic surgery. Swiss Med Wkly 2007 137 : 407 10.
3. Benharash P, Bongard F, Putnam B. Use of recombinant factor VIIa for adjunctive hemorrhage control in trauma and surgical patients. Am Surg 2005 71 : 776 80.
4. Eikelboom JW, Bird R, Blythe D, Coyle L, Gan E, Harvey M, Isbister J, Leahy M, Mcllroy D, Rahimpanah F, Ramanthan S, Strasser S, Ward C, Watts A, Towler S, Yi Q. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 2003 14 : 713 7.
5. Friederich PW, Herny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003 361 : 201 5.
6. Ganguly S, Spengel K, Tilzer LL, O'Neal B, Simpson SQ. Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome. Clin Lab Haematol 2006 28 : 309 12.
7. Grounds RM, Seebach C, Knothe C, Paluszkiewicz P, Smith TS, Kasal E, Lecumberri R, Urbanec R, Haas T, Wujtewicz M, Rehorkova D, Pelichovska M, Lange M, Uranga M, Bosman R, Rommes JH, Koscielny J. Use of recombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry. J Intensive Care Med 2006 21 : 27 39.
8. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008 358 : 2127 37.
9. Lodge JP, Jonas S, Oussoultzoglou E, Malago M, Jayr C, Cherqui D, Anthuber M, Mirza DF, Kuhlman L, Bechstein WO, Diaz JC, Tartiere J, Eyraud D, Fridberg M, Erhardtsen E, Mimoz O. Recombinant coagulation factor VIIa in major liver resection - a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005 102 : 269 75.
10. Lodge JP, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S, Garcia-Valdecasas JC, McAlister V, Mirza DF. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005 11 : 973 9.
11. Pugliese F, Ruberto F, Summonti D, Perrella S, Cappannoli A, Tosi A, D'alio A, Bruno K, Martelli S, Celli P, Morabito V, Rossi M, Berloco PB, Pietropaoli P. Activated recombinant factor VII in orthotopic liver transplantation. Transplant Proc 2007 39 : 1883 5.
12. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005 95 : 596 602.
13. Ekert H, Brizard C, Eyers R, Cochrane A, Henning R. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 2006 17 : 389 95.
14. Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez AJ, Fabricius S, Erhardtsen E, de Franchis R. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004 127 : 1123 30.
15. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma Injury Infect Crit Care 2005 59 : 8 16.
16. Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2007 CD005011.
17. White B, McHale J, Ravi N, Reynolds J, Stephens R, Moriarty J, Smith OP. Successful use of recombinant FVIIa (Novoseven®) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999 107 : 677 8.
18. Segal S, Shemesh IY, Blumenthal R, Yoffe B, Laufer N, Ezra Y, Levy I, Mazor M, Martinowitz U. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa). Arch Gynecol Obstet 2003 268 : 266 7.
19. Laffan MA, Tait RC, Blatny J, Espersen K, Grabowska I, Loch-Bakonska L, Pauzkowska A, Stasiak-Pikula E, Michalska G, Wendon J, Piotrowska K. Use of recombinant activated factor VII for bleeding in pancreatitis - a case series. Pancreas 2005 30 : 279 84.
20. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002 49 : S15 S20.
21. Bartal C, Freedman J, Bowman K, Cusimano M. Coagulopathic patients with traumatic intracranial bleeding: defining the role of recombinant factor VIIa. J Trauma 2007 63 : 725 32.
22. Hallevi H, Gonzales NR, Barreto AD, Martin-Schild S, Albright KC, Noser EA, Illoh K, Khaja AM, Allison T, Escobar MA, Shaltoni HM, Grotta JC. The effect of activated factor VII for intracerebral hemorrhage beyond 3 hours versus within 3 hours. Stroke 2008 39 : 473 5.
23. Brandsborg S, Sorensen B, Poulsen LH, Ingerslev J. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients. Blood Coagul Fibrinolysis 2006 17 : 241 9.
24. Harvey MP, Greenfield TP, Sugrue ME, Rosenfeld D. Massive blood transfusion in a tertiary referral hospital. Clinical outcomes and haemostatic complications. Med J Aust 1995 163 : 356 9.
25. Sawyer PR, Harrison CR. Massive transfusion in adults. Diagnoses, survival and blood bank support. Vox Sang 1990 58 : 199 203.
26. Sauaia A, Moore FA, Moore EE, Moser KS, Brennan R, Read RA, Pons PT. Epidemiology of trauma deaths: a reassessment. J Trauma 1995 38 : 185 93.